A new pill-form GLP-1 medication has demonstrated the ability to significantly lower blood sugar levels and reduce body weight in people with type 2 diabetes, potentially opening doors for millions who avoid injectable treatments due to needle anxiety. The oral drug elecoglipron, tested in a phase 2b clinical trial called SOLSTICE, achieved an average blood sugar reduction of 7% and helped up to 72.3% of participants lose at least 5% of their body weight over 26 weeks.

Until recently, GLP-1 (glucagon-like peptide-1) medications like Ozempic and Zepbound were only available as self-injections. About 12% of American adults currently take a GLP-1 medication for weight loss or type 2 diabetes management, but roughly 30% of adults experience trypanophobia, or a fear of injections, which has kept them from accessing these treatments.

Why Does an Oral Option Matter for Diabetes Treatment?

The shift toward pill forms represents a significant change in how diabetes medications are delivered. The FDA approved an oral version of Wegovy for weight loss in December 2025, followed by the once-daily oral GLP-1 drug Foundayo (orforglipron) in April 2026, both for weight loss. Now elecoglipron joins the pipeline as a potential treatment specifically for type 2 diabetes.

Experts emphasize that having multiple delivery options isn't just about convenience; it's about ensuring patients actually stick with their treatment. Many people stop taking GLP-1 medications not because of the needle itself, but due to side effects, cost, or lifestyle factors. Removing barriers to access, whether that's the injection itself or other practical concerns, keeps more people on therapies that work.

"Expanding oral GLP-1 options could help many patients access effective treatment who might otherwise never start therapy because they don't want injections. Ultimately, our goal is not to find one medication that works for everyone. Our goal is to give patients multiple evidence-based options so they can choose the treatment that best fits their lifestyle, preferences, health needs, and price point to make long-term use a viable option," said Amy Sheer, MD, MPH, DABOM, associate professor of medicine and program director of the Obesity Medicine Fellowship at the University of Florida.

Amy Sheer, MD, MPH, DABOM, associate professor of medicine and program director of the Obesity Medicine Fellowship at the University of Florida

How Does Elecoglipron Work to Lower Blood Sugar?

Elecoglipron is classified as an oral small molecule GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that helps regulate blood sugar. Unlike injectable GLP-1 medications, it can be taken as a daily pill.

In the SOLSTICE trial, participants taking elecoglipron at all tested dosages experienced significantly greater reductions in glucose levels compared to those receiving a placebo after 26 weeks. Importantly, participants achieved an HbA1c level of 7%, a key marker that reflects average blood sugar control over three months.

"This is clinically meaningful as we know that we can reduce the risk of diabetes-related complications through achievement and maintenance of glycemic targets, with the target of less than 7% as the generally accepted standard," explained Vanita Aroda, MD, director of Diabetes Clinical Research at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School.

Vanita Aroda, MD, director of Diabetes Clinical Research at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School

What Are the Key Benefits Beyond Blood Sugar Control?

The study revealed multiple benefits that extend beyond glucose management. GLP-1 receptor agonists work in part by decreasing appetite, which contributes to weight loss. Since many people with type 2 diabetes also carry excess weight or obesity, achieving even modest weight loss can improve both blood sugar control and broader heart and metabolic health.

• Weight Loss Achievement: Up to 72.3% of participants in the treatment group lowered their weight by at least 5%, a threshold shown to improve glucose control and reduce cardiometabolic risk factors
• Practical Administration: An oral pill is easier to transport and administer than injectable medications, particularly for people who travel frequently or dislike needles
• Manufacturing Potential: Pills may be cheaper to manufacture compared to injectable formulations, which could eventually lower costs for patients

Beyond these immediate benefits, experts note that oral GLP-1 options could increase competition in the market, potentially driving down costs and expanding the overall safety profile of GLP-1 drugs.

What Questions Remain About Elecoglipron?

While the 26-week trial results are encouraging, researchers and clinicians emphasize that more extensive testing is needed before elecoglipron becomes widely available. The next critical step would be a phase 3 clinical trial involving thousands of patients over a year or longer to confirm where blood sugar and weight effects actually stabilize.

Equally important are long-term cardiovascular and kidney outcomes. Injectable GLP-1 medications earned their prominent place in diabetes treatment by proving they prevent heart attacks, strokes, and kidney decline in dedicated outcomes trials. Elecoglipron will need to demonstrate similar protections to meet modern standards for type 2 diabetes care.

Additional research should also examine different starting doses and escalation speeds to understand how they impact side effects, as well as head-to-head comparisons with oral GLP-1 options already available. Finally, the practical question of cost and insurance coverage will ultimately determine whether this new option becomes accessible to patients who need it.

"A medicine only helps if the patient actually takes it," noted George W. Carroll, MD, co-founder and chief medical director of GLPrelief and founder of BeSlimMD in Maitland, Florida.

George W. Carroll, MD, co-founder and chief medical director of GLPrelief and founder of BeSlimMD in Maitland, Florida

The emergence of oral GLP-1 medications represents a meaningful shift in diabetes treatment options. By removing the barrier of needle anxiety and offering patients choice in how they take their medication, these new formulations could help more people access effective diabetes management and maintain their treatment long-term.